Palatin Reports Third Quarter Fiscal Year 2023 Financial Res

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical...

Related Keywords

United States , New Jersey , Cranbury , American , Carl Spana , Prnewswire Palatin Technologies Inc , Securities Exchange , Jersey Economic Development Authority , Palatin Technologies Inc , Dilutive Funding Through Nj Economic Development Program , Jersey Technology Business Tax Certificate Transfer Program , Association Of Research , International Journal Of Molecular Sciences , Dry Eye Disease Presented , Lead In Population , Showed Statistical Separation , Clinical Efficacy Across Multiple Signs , Dry Eye , Excellent Patient Safety , Data Expected Second Half Calendar Year , Ulcerative Colitis , Analysis Targeted , Second Half Calendar Year , Product Revenue Increased , Dispensed Increased , Non Dilutive Funding Through , Key Opinion Leader , International Journal , Sexual Desire , New Jersey Economic Development , Third Quarter Ended March , Eastern Time , Melanocortin Receptor Agonists , Palatin Technologies , Securities Exchange Act , Private Securities , Months Ended March , Seriesc Redeemable Convertible Preferred Stock , Nc ,